The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced b...
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological ...
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support developm...
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubl...
Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...
Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE) announced compelling five-year overall survival (OS) results from the open-label exten...
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (tra...
Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a n...
Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, announced that its collaboration par...
Exclusive licensing and R&D collaboration accelerate the development of a novel gene vector platform for precision gene therapy in Hepatocellular Car...
To mark Bladder Cancer Awareness Month this May, bladder health brand Jude has conducted new research into how much charitable funding is allocat...
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...
© 2025 Biopharma Boardroom. All Rights Reserved.
